All In Biotech

Drug Trial Radar · NCT07018752

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

A Platform Trial, Evaluating New Drugs or Combination in Relapsed or Refractory Peripheral T-cell Lymphomas

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Aug 20, 2025

Primary completion

Apr 2028

Study completion Jan 2030

Sponsor

Lead sponsor
The Lymphoma Academic Research OrganisationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
iOnctura; AbbVie; Bristol-Myers Squibb
First posted
Jun 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a platform trial for the evaluation of new drugs or combination of drugs in relapsed or refractory peripheral T-cell lymphomas. The objective of the study is to generate exploratory data on new drugs or combination of drugs to treat refractory/relapse peripheral T-cells lymphoma to better identify the population of interest and design future correct clinical trials. Primary objectives of the different sub-studies : * phase 1 sub-studies: determine the safety and tolerability of escalating doses of the sub-study treatment * phase 2 sub-studies: identify drugs that will improve significantly the outcome in target patients Secondary objectives of all sub-studies: analyze the response rate, the clinical benefit rate, the progression-free survival, the duration of response, the time to next treatment or death, the overall survival, the rate of transplantation following study treatment and the safety profile of the drugs used

Conditions

  • Peripheral T Cells Lymphoma (PTCL)
  • Follicular Helper T-Cell Lymphoma

Interventions

  • roginolisibDrug

    Roginolisib daily intake

  • golcadomideDrug

    Golcadomide daily intake

  • azacitidineDrug

    oral 5-azacitidine daily intake

  • VenetoclaxDrug

    Venetoclax daily intake

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified Progression-Free SurvivalTime frame: From enrollment to end of follow-up period of Origina-ly-T (= maximum 2 years after enrollment)
  2. Maximum Tolerated DoseTime frame: From enrollment to end of treatment of sub-study GolcAza (= maximum 2 years from enrollment)
  3. Recommended Phase II DoseTime frame: From enrollment to end of treatment of sub-study GolcAza (= maximum 2 years from enrollment)

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • CHU D'ANGERS - Service des Maladies du Sang

    Angers, France · Recruiting

  • Institut d'Hématologie de Basse Normandie - Service Hématologie (CHU Hôpital Côte de Nacre)

    Caen, France · Recruiting

  • CHU Estaing - Service Thérapie Cellulaire et Hématologie Clinique

    Clermont-Ferrand, France · Recruiting

  • Hôpital Henri Mondor - Unité Hémopathies Lymphoïdes

    Créteil, France · Recruiting

  • CHU Dijon Bourgogne - Service Hématologie Clinique

    Dijon, France · Recruiting

  • CHU de Grenoble - Service Hématologie

    La Tronche, France · Recruiting

  • CH du Mans - Centre de Cancérologie de la Sarthe - Service Hématologie

    Le Mans, France · Recruiting

  • CHU de Lille - Hôpital Claude Huriez - Service des Maladies du Sang

    Lille, France · Recruiting

  • Institut Paoli Calmettes - Service Hématologie

    Marseille, France · Not yet recruiting

  • CHU de Montpellier - Département d'Hématologie Clinique

    Montpellier, France · Recruiting

  • CHU de Nantes - Service Hématologie

    Nantes, France · Recruiting

  • Hôpital Necker - Service Hématologie Adultes

    Paris, France · Recruiting

  • CHU de Bordeaux - Hôpital Haut-Lévêque - Centre François Magendie - Service d'Hématologie et Thérapie Cellulaire

    Pessac, France · Recruiting

  • CHU Lyon-Sud - Hématologie Clinique

    Pierre-Bénite, France · Recruiting

  • CHU de Poitiers - Hôpital de la Milétrie - Service d'Oncologie Hématologique et Thérapie Cellulaire

    Poitiers, France · Recruiting

  • CHU Pontchaillou - Hématologie Clinique

    Rennes, France · Recruiting

  • Centre Henri Becquerel - Service Hématologie

    Rouen, France · Recruiting

  • Institut de Cancérologie et d'Hématologie Universitaire de Saint-Étienne - Service Hématologie

    Saint-Etienne, France · Recruiting

  • CH de la Côte Basque - Service Hématologie

    Saint-Jean-de-Luz, France · Recruiting

  • CHRU Nancy - Hôpital Brabois - Service Hématologie

    Vandœuvre-lès-Nancy, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.